Media coverage about Galena Biopharma (NASDAQ:GALE) has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galena Biopharma earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.7759143688681 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Galena Class Settlement Must Proceed, Del. Court Says (law360.com)
- Where Galena Biopharma Inc (GALE) Stands In Terms Of Earnings Growth Against Its Industry (finance.yahoo.com)
- What is ATR in technical analysis? Galena Biopharma, Inc. (GALE) – Wall Street Morning (wallstreetmorning.com)
- Investors may need a consensus Analysts Rating: Galena Biopharma, Inc. (GALE) – Wall Street Morning (wallstreetmorning.com)
Separately, Maxim Group reissued a “hold” rating on shares of Galena Biopharma in a research note on Wednesday, August 9th.
Galena Biopharma (GALE) opened at $0.28 on Wednesday. Galena Biopharma has a 12 month low of $0.26 and a 12 month high of $3.60.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://ledgergazette.com/2017/12/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-galena-biopharma-gale-share-price.html.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.